Neuromodulation to treat physiological conditions
The subject matter of the present disclosure generally relates to techniques for applying focused ultrasound energy to a region of interest in a subject to induce neuromodulation of the celiac plexus to treat inflammatory bowel disease. The region of interest ay include at least a portion of a peripheral ganglion of the celiac plexus.
1. A system, comprising:
an ultrasound probe configured to apply focused ultrasound energy to a region of interest comprising at least a portion of a celiac plexus in a subject to neuromodulate a peripheral ganglion of the celiac plexus of the subject; and
a controller configured to:
acquire image data of the subject from the ultrasound probe operating in an imaging mode;
identify anatomical landmarks in the image data, wherein the anatomical landmarks comprise a junction of at least one of a hepatic artery and splenic artery with an abdominal aorta;
automatically select the region of interest based on the anatomical landmarks adjacent to the peripheral ganglion of the celiac plexus identified in the image data;
control the ultrasound probe to apply the focused ultrasound energy to the region of interest as part of a treatment protocol to treat inflammatory bowel disease in the subject, wherein applying the focused ultrasound energy to the region of interest causes a change in concentration of one or more molecules of interest in the subject relative to a baseline concentration, wherein the one or more molecules of interest comprises one or more of interleukin (IL)-1, tumor necrosis factor (TNF-a), or interferon-gamma (IFN-y); and
detect the change in concentration.
2. The system of claim 1 , wherein the ultrasound probe comprises a therapy transducer configured to apply the focused ultrasound energy and an imaging probe configured to acquire the image data.
3. The system of claim 1 , wherein the region of interest comprises at least a portion of a peripheral ganglion of the celiac plexus.
4. The system of claim 1 , wherein the treatment protocol comprises applying the ultrasound energy to the region of interest at least daily over a plurality of days.
5. The system of claim 1 , wherein the controller is configured to:
cause a display of the image data;
receive a user input indicative of the region of interest in the displayed image data; and
select the region of interest based on the user input.
6. The system of claim 1 , wherein the one or more molecules of interest further comprises perinuclear anti-neutrophil antibody, anti- Saccharomyces Cerevisiae antibody, calprotectin, C-reactive protein, or anti-flagellin antibody.
7. The system of claim 1 , wherein applying the focused ultrasound energy to the region of interest causes enteric cholinergic anti-inflammatory pathway (CAP) stimulation.
8. The system of claim 7 , wherein applying the focused ultrasound energy to the region of interest does not cause splenic CAP stimulation or causes relatively less splenic CAP stimulation relative to enteric CAP stimulation.
9. The system of claim 1 , comprising assessing a response to the focused ultrasound energy over a period of time; and changing a treatment protocol to change a dose frequency based on the assessing.
10. The system of claim 1 , wherein applying the focused ultrasound energy to the region of interest results in an improvement of a DAI score of the subject relative to a baseline DAI score, wherein the baseline DAI score is determined prior to the applying.
11. A method, comprising:
acquiring image data of a subject from an ultrasound probe operating in an imaging mode, wherein the subject is diagnosed with inflammatory bowel disease;
identifying anatomical landmarks in the image data, wherein the anatomical landmarks comprise a junction of at least one of a hepatic artery and splenic artery with an abdominal aorta;
automatically selecting a region of interest comprising at least a portion of a celiac plexus based on the anatomical landmarks adjacent to a peripheral ganglion of the celiac plexus identified in the image data; and
controlling the ultrasound probe to apply focused ultrasound energy to the region of interest as part of a treatment protocol to treat the inflammatory bowel disease, wherein the region of interest comprises at least a portion of the peripheral ganglion of the celiac plexus, wherein applying the focused ultrasound energy to the region of interest causes a change in concentration of one or more molecules of interest in the subject relative to a baseline concentration, wherein the one or more molecules of interest comprises one or more of interleukin (IL)-1, tumor necrosis factor (TNF-a), or interferon-gamma (IFN-y); and
detecting the change in concentration.
12. The method of claim 11 , wherein the one or more molecules of interest further comprises one or more of IL-12 or IL-10.
13. The method of claim 11 , wherein the subject has a diagnosis of Crohn's disease.
14. The method of claim 11 , wherein the subject has a diagnosis of ulcerative colitis.
15. The method of claim 11 , wherein applying the focused ultrasound energy to the region of interest results in an improvement of a disease activity index (DAI) score of the subject relative to a baseline DAI score, wherein the baseline DAI score is determined prior to the applying.
16. The method of claim 11 , wherein applying the focused ultrasound energy to the region of interest results in a reduction in a stool blood level relative to a baseline stool blood level determined prior to the applying.